Marker Therapeutics, Inc.

Daily Archives: Thursday, October 18, 2018

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 18th begins trading under the ticker (NASDAQ: MRKR), retiring TapImmune’s ticker (TPIV).

Read More

Marker to Present at Two Upcoming Cellular Therapy Conferences

Marker Therapeutics, Inc. President and CEO, Peter L. Hoang, will be participating in conferences next week.

Read More